Last reviewed · How we verify
AZD9833 with anastrozole
Estrogen receptor inhibitor
Estrogen receptor inhibitor Used for Hormone receptor-positive breast cancer.
At a glance
| Generic name | AZD9833 with anastrozole |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SERD |
| Target | Estrogen receptor alpha (ERα) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD9833 is a selective estrogen receptor degrader (SERD) that inhibits estrogen receptor alpha (ERα) signaling, which is involved in the growth and survival of hormone receptor-positive breast cancer cells.
Approved indications
- Hormone receptor-positive breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
Key clinical trials
- Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (PHASE3)
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (PHASE3)
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (PHASE1)
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (PHASE3)
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (PHASE3)
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9833 with anastrozole CI brief — competitive landscape report
- AZD9833 with anastrozole updates RSS · CI watch RSS
- AstraZeneca portfolio CI